Pfizer Indian arm reports profit jump on lower costs, price hikes
Pfizer's revenue from operations rose 0.3% to 6.38 billion rupees.
Bengaluru: Pfizer Ltd, the Indian arm of U.S. pharma giant Pfizer Inc, reported a rise in second-quarter profit on Friday, boosted by price hikes and lower input costs.
Profit before tax and exceptional item rose to 2.26 billion Indian rupees ($27.97 million) in the three months ended Sept. 30, from 1.75 billion rupees in the year-ago period.
The company booked a one-time gain of 1.89 billion rupees on the sale its off-patent and generic medicines business, Upjohn.
Pfizer's revenue from operations rose 0.3% to 6.38 billion rupees.
Its cost of materials consumed fell 2.1% to 944 million rupees, accounting for about 21% of total expenses in the quarter.
Read also: Cipla reports bigger-than-expected 11 percent increase in Q2 profit
Though the volume of drug sales in India took a hit last quarter, drugmakers benefited from price hikes and product launch-led growth, BOB Capital Markets said in a recent note.
The Indian pharma market grew 8.2% year-over-year in value terms during the July-September quarter, supported by higher revenue from medicines treating chronic illnesses even though volumes were flat, analysts at ICICI Securities said in a note.
Read also: JB Pharma records revenue growth of 36 percent to Rs 809 crores in Q2 FY23
Pfizer's shares have fallen nearly 13% this year, while the Nifty Pharma index has shed about 9%.
Earlier in the day, peer Zydus Lifesciences reported an 82.6% slump in second-quarter profit, hit by rising expenses.
Read also: Pfizer-BioNTech COVID booster targeting Omicron BA.4/5 approved in Britain
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.